No information is available on the clinical use of tepotinib during breastfeeding. Because tepotinib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 32 hours, the manufacturer recommends that breastfeeding be discontinued during tepotinib therapy and for 1 week after the last dose.
关于替泊替尼在母乳喂养期间的临床应用尚无可用信息。由于替泊替尼与血浆蛋白的结合率为98%，其在乳汁中的含量可能较低。然而，鉴于其对母乳喂养婴儿具有潜在毒性且半衰期为32小时，制造商建议在替泊替尼治疗期间及最后一剂后1周内停止母乳喂养。
